Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359429 | 0.80 | CYP3A4 (0.36) | CYP3A4KDM4EBRD4 | |
| SCHEMBL1971791 | 0.78 | IMPDH2 (0.47) | MCL1KDM4EALDH1A1BRD4IMPDH2 | |
| SCHEMBL1358987 | 0.75 | CYP3A4 (0.40) | CYP3A4KDM4EALDH1A1GAABRD4 | |
| SCHEMBL1359884 | 0.69 | CYP3A4 (0.35) | MCL1CYP3A4 | |
| SCHEMBL12138690 | 0.69 | CHEK1 (0.37) | CYP3A4BRD4 | |
| SCHEMBL1357997 | 0.69 | CYP3A4 (0.40) | MCL1CYP3A4 | |
| SCHEMBL1543883 | 0.68 | CYP3A4 (0.61) | MCL1CYP3A4KDM4EALDH1A1GAA | |
| SCHEMBL1360035 | 0.68 | BRD4 (0.40) | CYP3A4BRD4 | |
| SCHEMBL1543881 | 0.68 | CYP3A4 (0.61) | MCL1CYP3A4KDM4EALDH1A1GAA | |
| SCHEMBL1358251 | 0.65 | CYP3A4 (0.38) | CYP3A4KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | claimed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | MCL1 2162/4885CYP3A4 713/4885KDM4E 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.